Year: 2015
Type: review
Abstract: Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes. From the clinical editor: Many nervous system disorders remain unresolved clinical problems. In many cases, drug agents simply cannot cross the blood-brain barrier (BBB) into the nervous system. The advent of nanomedicines can enhance the delivery of biologically active molecules for targeted therapy and imaging. This review focused on the use of nanotechnology for degenerative, inflammatory, and infectious diseases in the nervous system.
Institutions: University of Nebraska Medical Center, Iowa State University
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $3,670
Funders: University of Nebraska Medical Center, ViiV Healthcare, National Institutes of Health, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, Medical Research and Materiel Command
Awards: G1167065520, Neuroprotection by Mitochondria-targeted Antioxidants, NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence, Neuronanomedicine, Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center, T Cell-Mediated Neurodegeneration in Parkinson's Disease, Nanomedicine and NeuroAIDS, Mechanisms of Manganese Neurotoxicity, G4700852728, Novel Adjunctive Therapies for NeuroAIDS, Role of Prion Protein in Manganese Neurotoxicity, Molecular Mechanisms of HIV-1 Associated Encephalopathy, G5850682332, Nebraska Center for Nanomedicine, SMART HAND, Oxidative Stress Induced Compensatory Protective Mechanisms in PD, Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1, Neural Immunity in HIV Dementia, Neuroprotective Immunity and HIV Dementia
OpenAlex ID: W2063347334
